- Home
- PKG vs INCY Comparison
PKG vs INCY Comparison
Compare PKG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKG
- INCY
- Stock Information
- Founded
- PKG 1867
- INCY 1991
- Country
- PKG United States
- INCY United States
- Employees
- PKG N/A
- INCY N/A
- Industry
- PKG Containers/Packaging
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PKG Consumer Discretionary
- INCY Health Care
- Exchange
- PKG Nasdaq
- INCY Nasdaq
- Market Cap
- PKG 16.6B
- INCY 13.4B
- IPO Year
- PKG 2000
- INCY 1993
- Fundamental
- Price
- PKG $187.19
- INCY $58.21
- Analyst Decision
- PKG Strong Buy
- INCY Hold
- Analyst Count
- PKG 6
- INCY 20
- Target Price
- PKG $239.83
- INCY $74.00
- AVG Volume (30 Days)
- PKG 1.0M
- INCY 2.3M
- Earning Date
- PKG 04-22-2025
- INCY 04-29-2025
- Dividend Yield
- PKG 2.67%
- INCY N/A
- EPS Growth
- PKG 5.31
- INCY N/A
- EPS
- PKG 8.93
- INCY 0.15
- Revenue
- PKG $8,383,299,999.00
- INCY $4,241,216,999.00
- Revenue This Year
- PKG $7.31
- INCY $12.21
- Revenue Next Year
- PKG $3.23
- INCY $9.20
- P/E Ratio
- PKG $20.96
- INCY $345.39
- Revenue Growth
- PKG 7.45
- INCY 14.76
- 52 Week Low
- PKG $169.00
- INCY $50.35
- 52 Week High
- PKG $250.82
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- PKG 43.03
- INCY 40.69
- Support Level
- PKG $185.52
- INCY $57.05
- Resistance Level
- PKG $193.53
- INCY $59.95
- Average True Range (ATR)
- PKG 7.84
- INCY 2.76
- MACD
- PKG 0.40
- INCY 0.18
- Stochastic Oscillator
- PKG 48.64
- INCY 46.45
About PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 4.5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.